Table 2.
Summary of primary and secondary endpoints at weeks 24, 52 and 104
| Endpoint, n (%) unless stated | Week | Secukinumab 150 mg (n = 213) | Secukinumab 75 mg (n = 210) | Placebo (n = 214) |
|---|---|---|---|---|
| ACR20a | 24 | 75 (35.2)* | 74 (35.2)* | 42 (19.6) |
| 52 | 88 (61.5) | 75 (57.7) | N/A | |
| 104 | 50 (69.4) | 50 (74.6) | N/A | |
| ACR50a | 24 | 34 (16.0)* | 37 (17.6)* | 14 (6.5) |
| 52 | 36 (27.7) | 34 (23.8) | N/A | |
| 104 | 28 (38.9) | 25 (37.3) | N/A | |
| ACR70a | 24 | 8 (3.8) | 17 (8.1)* | 5 (2.3) |
| 52 | 14 (9.8) | 13 (10.0) | N/A | |
| 104 | 12 (16.7) | 9 (13.4) | N/A | |
| HAQ-DIb | 24 | − 0.4 (0.0) | − 0.4 (0.0) | − 0.2 (0.1) |
| 52 | − 0.4 (0.6) | − 0.4 (0.6) | N/A | |
| 104 | − 0.5 (0.7) | − 0.5 (0.7) | N/A |
ACR American College of Rheumatology, CRP C-reactive protein, DAS28 disease activity score in 28 joints, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, N/A not assessed, SD standard deviation, SE standard error
a Non-responder imputation data at week 24 and observed data at week 52, n (%)
b Mixed-effect model repeated measures (MMRM) ± SE data at week 24 and observed data ± SD at week 52
* P < 0.05 for secukinumab vs placebo